Please login to the form below
Healthcare terms - P
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W |
Healthcare Glossary
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W |
Healthcare terms - P
- Packaging
- Pandemic
- Parallel importing
- Pareto principle
- Patent
- Payback period
- Payment by results (PBR)
- Peer review
- Peer to peer (P2P) marketing
- PEEST
- Penetrated market
- Penetration pricing
- Perfect competition
- Performance prism
- Persistence
- Personal data
- Personal selling
- PESTLE
- Pharmaceutical Pricing Regulation Scheme (PPRS)
- Pharmaceutical Researchers and Manufacturers of America (PhRMA)
- Pharmacokinetics
- Pharmacy Benefit Manager (PBM)
- Phase I trials
- Phase II trials
- Phase III trials
- Phase IV trials
- Pilot programme
- Placebo
- Placebo effect
- Placebo-controlled trial
- Point of sale (POS)
- Point-of-purchase displays
- Porter's 'Five Forces'
- Portfolio
- Portfolio analysis
- Positioning
- Post detail survey
- Post-testing
- Practice Based Commissioning (PBC)
- Pre-clinical trials
- Preferred provider organisation (PPO)
- Premium pricing
- Prescribing Analysis and Cost (PACT)
- Prescribing information
- Prescription Medicines Code of Practice Authority (PMCPA)
- Prescription only medicine (POM)
- Press release
- Prevention trials
- Price fixing
- Price maker
- Price taker
- Primary care
- Primary Care Trust (PCT)
- Prior approval
- Procurement officer/manager
- Product attributes
- Product class
- Product differentiation
- Product pipeline
- Promotional mix
- Promotional plan
- Prompted recall
- Prophylaxis
- Proprietary name
- Protocol
- Public relations
- Publication planning
- Publics
- Pull promotion
- Purchasing power parities (PPP)
- Push promotion
- “P” Medicine
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- ONS data reveals significant decrease in COVID-19 antibodies
- Bristol Myers Squibb and GentiBio in $1.9bn deal to develop IBD therapies
- UK government’s ‘science superpower’ ambitions to fail without clear plan, Lords committee warns
- WHO releases interim statement on COVID-19 vaccination for children and adolescents
- Novartis reports death of two patients treated with Zolgensma
- The impact of COVID-19 on the fight against AMR
- NHS bowel cancer checks reach record-high following death of Dame Deborah James
- Environment: where does the pharmaceutical industry stand?
- Moderna’s Omicron booster receives MHRA approval
- Sanofi halts recruitment for trials assessing MS treatment
- BeiGene announces positive phase 3 trial results for liver cancer treatment
- Amgen acquires ChemoCentryx in $3.7bn cash deal
- A creative awakening – how pharma is bringing innovation to the patient journey
- Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
